Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Thyroid-Stimulating Hormone Restores Bone Volume, Microarchitecture, and Strength in Aged Ovariectomized Rats (CROSBI ID 141096)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Kuber, Sampath T. ; Šimić, Petra ; Sendak, Rebecca ; Drača, Nataša ; Bowe, A. E. ; O'Brien, S. ; Schiavi, S. C. ; McPherson, J. M. ; Vukičević, Slobodan Thyroid-Stimulating Hormone Restores Bone Volume, Microarchitecture, and Strength in Aged Ovariectomized Rats // Journal of bone and mineral research, 22 (2007), 6; 849-859. doi: 10.1359/jbmr.070302

Podaci o odgovornosti

Kuber, Sampath T. ; Šimić, Petra ; Sendak, Rebecca ; Drača, Nataša ; Bowe, A. E. ; O'Brien, S. ; Schiavi, S. C. ; McPherson, J. M. ; Vukičević, Slobodan

engleski

Thyroid-Stimulating Hormone Restores Bone Volume, Microarchitecture, and Strength in Aged Ovariectomized Rats

We show the systemic administration of low levels of TSH increases bone volume and improves bone microarchitecture and strength in aged OVX rats. TSH’ s actions are mediated by its inhibitory effects on RANKL-induced osteoclast formation and bone resorption coupled with stimulatory effects on osteoblast differentiation and bone formation, suggesting TSH directly affects bone remodeling in vivo. Introduction: Thyroid-stimulating hormone (TSH) receptor haploinsufficient mice with normal circulating thyroid hormone levels have reduced bone mass, suggesting that TSH directly affects bone remodeling. We examined whether systemic TSH administration restored bone volume in aged ovariectomized (OVX) rats and influenced osteoclast formation and osteoblast differentiation in vitro. Materials and Methods: Sprague-Dawley rats were OVX at 6 months, and TSH therapy was started immediately after surgery (prevention mode ; n _ 80) or 7 mo later (restoration mode ; n _ 152). Hind limbs and lumbar spine BMD was measured at 2- or 4-wk intervals in vivo and ex vivo on termination at 8– 16 wk. Long bones were subjected to _CT, histomorphometric, and biomechanical analyses. The direct effect of TSH was examined in osteoclast and osteoblast progenitor cultures and established rat osteosarcoma-derived osteoblastic cells. Data were analyzed by ANOVA Dunnett test. Results: In the prevention mode, low doses (0.1 and 0.3 _g) of native rat TSH prevented the progressive bone loss, and importantly, did not increase serum triiodothyroxine (T3) and thyroxine (T4) levels in aged OVX rats. In restoration mode, animals receiving 0.1 and 0.3 _g TSH had increased BMD (10– 11%), trabecular bone volume (100– 130%), trabecular number (25– 40%), trabecular thickness (45– 60%), cortical thickness (5– 16%), mineral apposition and bone formation rate (200– 300%), and enhanced mechanical strength of the femur (51– 60%) compared with control OVX rats. In vitro studies suggest that TSH’ s action is mediated by its inhibitory effects on RANKL-induced osteoclast formation, as shown in hematopoietic stem cells cultivated from TSH-treated OVX rats. TSH also stimulates osteoblast differentiation, as shown by effects on alkaline phosphatase activity, osteocalcin expression, and mineralization rate. Conclusions: These results show for the first time that systemically administered TSH prevents bone loss and restores bone mass in aged OVX rats through both antiresorptive and anabolic effects on bone remodeling.

thyroid-stimulating hormone; thyrotropin; bone loss; ovariectomy; postmenopausal osteoporosis

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

22 (6)

2007.

849-859

objavljeno

0884-0431

10.1359/jbmr.070302

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost